Dudnyk Andrii, Lutchmun Wandini, Duarte Raquel, Lange Christoph, Svensson Elin M
Innovation in Respiratory Infections and Tuberculosis Diagnosis Group, Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain.
Department of Tuberculosis, Clinical Immunology and Allergy, National Pirogov Memorial Medical University, Vinnytsia, Ukraine.
Breathe (Sheff). 2025 Mar 18;21(1):240177. doi: 10.1183/20734735.0177-2024. eCollection 2025 Jan.
Prescribing the optimal combination of anti-tuberculosis drugs at the right dose is a fundamental step to achieve successful treatment outcomes. To aid the decision, clinicians should consider multiple factors, such as body weight, age, results of drug susceptibility testing, risk of intolerance and potential drug-drug interactions. In this viewpoint, we outline different aspects of dose selection in the treatment of tuberculosis (TB) such as traditional pharmacokinetics/pharmacodynamics, population pharmacokinetics models, the importance of real-world evidence and clinical trial design in the development of shorter treatment regimens and the new TB drug pipeline. Therapeutic drug monitoring for rifampicin, linezolid and amikacin may significantly improve their risk-benefit profile promoting their responsible administration. Precision dosing of novel, repurposed or conventional TB drugs should ensure optimal efficacy, while minimising toxicity and the development of resistance.
以正确剂量开具最佳抗结核药物组合是实现成功治疗效果的基本步骤。为辅助决策,临床医生应考虑多种因素,如体重、年龄、药敏试验结果、不耐受风险以及潜在的药物相互作用。在本文观点中,我们概述了结核病治疗中剂量选择的不同方面,如传统药代动力学/药效学、群体药代动力学模型、真实世界证据的重要性以及缩短治疗方案开发和新型结核病药物研发中的临床试验设计。对利福平、利奈唑胺和阿米卡星进行治疗药物监测可能会显著改善其风险效益状况,促进其合理使用。新型、重新利用或传统结核病药物的精准给药应确保最佳疗效,同时将毒性和耐药性的产生降至最低。